Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 7/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.44 |
| ▸ | F13A1 | P00488 | 2/20 | 0.43 |
| ▸ | TGM2 | P21980 | 2/20 | 0.43 |
| ▸ | TGM1 | P22735 | 2/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.43 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17765068 | 1.00 | SMN1; SMN2 (0.54) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL16333453 | 0.93 | SMN1; SMN2 (0.56) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL16340503 | 0.93 | SMN1; SMN2 (0.56) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL21458882 | 0.93 | SMN1; SMN2 (0.60) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL21458370 | 0.93 | SMN1; SMN2 (0.60) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL16340641 | 0.93 | SMN1; SMN2 (0.59) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL21906825 | 0.93 | SMN1; SMN2 (0.59) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL17765071 | 0.93 | SMN1; SMN2 (0.59) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL13519203 | 0.92 | SMN1; SMN2 (0.57) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL28563537 | 0.86 | SMN1; SMN2 (0.56) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11111214-B2 | Kappa opioid agonists and uses thereof | NEKTAR THERAPEUTICS (US) | 2021-09-07 | — | — | US | disclosed |
| US-11111214-B2 | Kappa opioid agonists and uses thereof | NEKTAR THERAPEUTICS (US) | 2021-09-07 | — | — | US | disclosed |
| US-20190352291-A1 | KAPPA OPIOID AGONISTS AND USES THEREOF | NEKTAR THERAPEUTICS | 2019-11-21 | — | — | US | disclosed |
| US-20190352291-A1 | KAPPA OPIOID AGONISTS AND USES THEREOF | NEKTAR THERAPEUTICS | 2019-11-21 | — | — | US | disclosed |
| EP-3013812-B1 | KAPPA OPIOID AGONISTS AND USES THEREOF | NEKTAR THERAPEUTICS (US) | 2019-10-16 | — | — | EP | disclosed |
| US-10407416-B2 | Kappa opioid agonists and uses thereof | NEKTAR THERAPEUTICS (US) | 2019-09-10 | — | — | US | disclosed |
| US-10407416-B2 | Kappa opioid agonists and uses thereof | NEKTAR THERAPEUTICS (US) | 2019-09-10 | — | — | US | disclosed |
| US-20180016266-A1 | KAPPA OPIOID AGONISTS AND USES THEREOF | NEKTAR THERAPEUTICS | 2018-01-18 | — | — | US | disclosed |
| US-20180016266-A1 | KAPPA OPIOID AGONISTS AND USES THEREOF | NEKTAR THERAPEUTICS | 2018-01-18 | — | — | US | disclosed |
| US-20180016266-A1 | KAPPA OPIOID AGONISTS AND USES THEREOF | NEKTAR THERAPEUTICS | 2018-01-18 | — | — | US | disclosed |
| US-9815824-B2 | Kappa opioid agonists and uses thereof | NEKTAR THERAPEUTICS (US) | 2017-11-14 | — | — | US | disclosed |
| US-9815824-B2 | Kappa opioid agonists and uses thereof | NEKTAR THERAPEUTICS (US) | 2017-11-14 | — | — | US | disclosed |
| US-9815824-B2 | Kappa opioid agonists and uses thereof | NEKTAR THERAPEUTICS (US) | 2017-11-14 | — | — | US | disclosed |
| US-20160145245-A1 | KAPPA OPIOID AGONISTS AND USES THEREOF | NEKTAR THERAPEUTICS | 2016-05-26 | — | — | US | disclosed |
| US-20160145245-A1 | KAPPA OPIOID AGONISTS AND USES THEREOF | NEKTAR THERAPEUTICS | 2016-05-26 | — | — | US | disclosed |
| US-20160145245-A1 | KAPPA OPIOID AGONISTS AND USES THEREOF | NEKTAR THERAPEUTICS | 2016-05-26 | — | — | US | disclosed |
| EP-3013812-A2 | KAPPA OPIOID AGONISTS AND USES THEREOF | Nektar Therapeutics (US) | 2016-05-04 | — | — | EP | disclosed |
| WO-2014210436-A2 | KAPPA OPIOID AGONISTS AND USES THEREOF | NEKTAR THERAPEUTICS (US) | 2014-12-31 | — | — | WO | disclosed |
| WO-2014210436-A2 | KAPPA OPIOID AGONISTS AND USES THEREOF | NEKTAR THERAPEUTICS (US) | 2014-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160145245-A1 | KAPPA OPIOID AGONISTS AND USES THEREOF | OPRK1, OPRD1, OPRM1 | SMN1; SMN2 1569/4885NPC1 1933/4885RAB9A 3516/4885 |
| US-20190352291-A1 | KAPPA OPIOID AGONISTS AND USES THEREOF | OPRK1, OPRD1, OPRM1 | SMN1; SMN2 1569/4885NPC1 1933/4885RAB9A 3516/4885 |
| US-11111214-B2 | Kappa opioid agonists and uses thereof | OPRK1, OPRD1, OPRM1 | SMN1; SMN2 1497/4885NPC1 1885/4885RAB9A 3491/4885 |
| US-20180016266-A1 | KAPPA OPIOID AGONISTS AND USES THEREOF | OPRK1, OPRD1, OPRL1 | SMN1; SMN2 2450/4885NPC1 3487/4885RAB9A 2285/4885 |
| US-10407416-B2 | Kappa opioid agonists and uses thereof | OPRK1, OPRD1, OPRL1 | SMN1; SMN2 2450/4885NPC1 3487/4885RAB9A 2285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.